21Jan/14

Illumina Inc.: Illumina Signs Master Supply Agreement to Provide Next … – The Wall Street Transcript

Illumina Inc.: Illumina Signs Master Supply Agreement to Provide Next
The Wall Street Transcript
“The HLA typing assays we are developing on Illumina’s family of NGS platforms will provide physicians with the ability to more accurately match bone marrow donors to recipients.” “We are excited to support LabCorp’s ability to offer more NGS-based

and more »

21Jan/14

Forecasting Earnings Growth And Profitability In The Biopharmaceutical Industry – Seeking Alpha

Forecasting Earnings Growth And Profitability In The Biopharmaceutical Industry
Seeking Alpha
had approval to market AVONEX® interferon beta-1a for multiple sclerosis, RITUXAN® rituximab for lymphoma and rheumatoid arthritis, TYSABRI® natalizumab for multiple sclerosis and Crohn’s disease, and FUMADERM® dimethylfumarate for psoriasis.

21Jan/14

Illumina (ILMN), Lab Corp (LH) Enter Multi-Year Supply Agreement – StreetInsider.com (subscription)

Illumina (ILMN), Lab Corp (LH) Enter Multi-Year Supply Agreement
StreetInsider.com (subscription)
“The HLA typing assays we are developing on Illumina’s family of NGS platforms will provide physicians with the ability to more accurately match bone marrow donors to recipients.” “We are excited to support LabCorp’s ability to offer more NGS-based

and more »